CLINICAL TRIALS PROFILE FOR RHOPRESSA
✉ Email this page to a colleague
All Clinical Trials for RHOPRESSA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03808688 ↗ | Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting | Completed | Aerie Pharmaceuticals | Phase 4 | 2018-12-27 | To evaluate the IOP lowering efficacy of netarsudil ophthalmic solution 0.02% when used as monotherapy or when used concomitantly with other IOP-lowering agents in subjects with elevated IOP due to open angle glaucoma or ocular hypertension in a real-world clinical setting. The study is an open-label design. The patients will receive treatment for 12 weeks. |
| NCT03971357 ↗ | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration | Terminated | Cornea Research Foundation of America | Phase 2/Phase 3 | 2019-07-22 | Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer. |
| NCT03971357 ↗ | Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration | Terminated | Price Vision Group | Phase 2/Phase 3 | 2019-07-22 | Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer. |
| NCT04051463 ↗ | Rhopressa for Corneal Edema Associated With Fuchs Dystrophy | Completed | Price Vision Group | Phase 2/Phase 3 | 2019-08-05 | The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant. |
| NCT04981886 ↗ | Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma | Not yet recruiting | Salus University | Phase 4 | 2021-08-01 | Glaucoma is the second leading cause of blindness and the first leading cause of irreversible vision loss worldwide. The intraocular pressure (IOP) is the only modifiable risk factor for all the spectrum of glaucoma. Reducing IOP in glaucoma increases the likelihood of preventing progression of the disease and preserving the quality of life of the patient. Although prostaglandin analogs (PGAs) and prostamides (PMs) are de facto first-line treatment options for managing glaucoma, it is a common clinical experience to see their treatment effects plateau to a level beyond which no clinically significant IOP reduction is likely. It is also common to find minimal IOP treatment effects in the following conditions: patients with normal tension glaucoma (NTG), patients with thicker central corneal thickness (CCT), and patients with higher levels of corneal hysteresis (CH). CH is a possible proxy for the ability of the scleral tissue around the optic nerve to dissipate energy away from the optic nerve fibers. Netarsudil, a rho-kinase inhibitor was recently approved by the FDA for the treatment of glaucoma and ocular hypertension. There is a paucity of research on the efficacy of netarsudil in patients with NTG, thicker CCT, and higher levels of CH. This study aims to investigate the above issues by evaluating the efficacy of netarsudil and bimatoprost in subjects with NTG, thicker corneas, and higher levels of CH. Hypotheses - Netarsudil will have non-inferior efficacy compared to Bimatoprost in treating NTG. - Corneal thickness and corneal hysteresis will reduce the efficacy of netarsudil similar to bimatoprost in NTG. - Netarsudil will change corneal thickness and corneal hysteresis similar to bimatoprost in NTG. |
| NCT05660447 ↗ | A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR | Not yet recruiting | Wills Eye | Phase 2/Phase 3 | 2022-12-19 | The purpose of this study is to determine if a drug called netarsudil is safe and able to prevent the development of scar tissue after retinal detachment repair. Patients eligible for this study are those diagnosed with a rhegmatogenous retinal detachment deemed at high risk for scar tissue formation (a process called 'proliferative vitreoretinopathy'). |
| NCT06033703 ↗ | Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment | Not yet recruiting | Massachusetts Eye and Ear Infirmary | Phase 1/Phase 2 | 2024-02-01 | This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes. The second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RHOPRESSA
Condition Name
Clinical Trial Locations for RHOPRESSA
Trials by Country
Clinical Trial Progress for RHOPRESSA
Clinical Trial Phase
Clinical Trial Sponsors for RHOPRESSA
Sponsor Name
